The heart attack and the risk of stroke could drop with an experimental medication, discovers the study

A new daily pill could provide an easier and more practical way to reduce cholesterol and reduce the risk of heart attack and stroke.

The experimental medication, called Obitetrapib, has undergone a phase 3 clinical trial at Monash University in Australia.

The trial included more than 2,500 people with an average of 65 years. All had either a diagnosis of heart disease or had genetically high cholesterol, according to a press release from the university.

This essential of the pantry could be essential to reduce cholesterol, suggests new research

All participants received “maximum tolerated doses of mortgage treatment with cholesterol.

A group received the Obitetrapib and another group took a placebo, while maintaining their existing cholesterol medications.

A new daily pill could provide an easier and more practical way to reduce cholesterol and reduce the risk of heart attack and stroke. (istock)

After 12 weeks, participants taking the new medication showed a reduction of 32.6% of LDL cholesterol and a 33.5% drop in lipoprotein (A) (LP (A)), the press release said.

The results were presented last month at the Congress of the European Society of Atherosclerosis in the United Kingdom and were also published in the New England Journal of Medicine.

The risk of women’s heart disease could be predicted up to 30 years in advance with a blood test, the results of the study

“We know that many people at high risk of heart attack or stroke do not obtain their sufficiently low cholesterol levels, even on the best available treatments,” said Stephen Nicholls’ principal teacher, director of the Victorian Heart Institute of Monash University and Victorian Heart Hospital of Monash Health, in the press release.

“We know that many people at high risk of heart attack or stroke do not obtain their sufficiently low cholesterol levels, even on the best available treatments.”

“The Obletrapib offers a new promising option – not only did it drop LDL cholesterol by more than 30%, but we have also seen a reduction in LP (A), which is much more difficult to treat and has been linked to an increased risk of heart disease.”

Lipoprotein with low density (LDL), which is sometimes called “bad cholesterol”, is associated with negative health effects when present in high quantities. (istock)

Lipoprotein with low density (LDL), which is sometimes called “bad cholesterol”, is associated with negative health effects when present in high quantities.

LDL can accumulate in blood vessels and increase the risk of heart attack and stroke, have warned the researchers.

Click here to obtain the Fox News app

Lipoprotein (A), or LP (A), is a protein known to considerably increase the chances of a heart attack when present in high levels in the blood.

Unlike LDL, LP (A) is a hereditary risk factor that cannot be changed with healthy behaviors or medicines.

Lipoprotein (A), or LP (A), is a protein known to considerably increase the chances of a heart attack when present in high levels in the blood. (istock)

The Obletrapib turned out to be “well tolerated” by the participants, noted the researchers.

“This could be a precious tool in the fight against heart disease,” added Nicholls. “It’s practical, it’s effective and it can help fill the gap for patients who no longer have options.”

Click here to register for our Health Newsletter

The study – which was funded by Newamsterdam Pharma, an Obitrapib developer based in the Netherlands – had certain limits, noted the researchers.

The Obletrapib turned out to be “well tolerated” by the participants, noted the researchers. (istock)

For example, participants were not chosen on the basis of high LP (A), which means that the study did not determine how the drug had an impact on those who have high protein levels.

In addition, the study evaluated changes in LDL levels, but did not measure the real results of heart attack or stroke.

For more health items, visit www.foxnews.com/health

Other studies are necessary to follow patients for longer periods and to include more diverse cohorts, have recognized the researchers.

Fox News Digital contacted researchers for additional comments.